Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex as Adjunct to Botox in Blepharospasm
NCT04423341Phase 3Completed
- Sponsor
- Silkiss Eye Surgery
- Start
- May 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cannabidiol in benign essential blepharospasm (BEB), sponsored by Silkiss Eye Surgery. Started May 2020; status: completed.
02
Drugs
cannabidiol
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT04423341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423341.